GlassScriptPhysician profile
Krishna Sury
NPI 1780020073
$4,328.30
in general payments reported to CMS, 2019-2025
31 companies · $296 in 2025
The $296 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $195 · 2021: $836 · 2022: $891 · 2023: $935 · 2024: $1,006 · 2025: $296.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,945 · Education: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.20 |
| Education | $292.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $494.32 | 2022-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $466.33 | 2020-2025 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $438.85 | 2021-2025 | |
| Amgen INC. | $278.80 | 2020-2025 | Krystexxa, Aranesp, Uplizna |
| Travere Therapeutics, INC. | $240.15 | 2022-2025 | Filspari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.93 | 2021-2024 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $180.16 | 2020-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $165.57 | 2022-2025 | |
| Akebia Therapeutics INC | $153.33 | 2019-2024 | Vafseo, Auryxia |
| Novo Nordisk INC | $144.81 | 2020-2023 | Rybelsus, Ozempic |
| Opko Pharmaceuticals, LLC | $136.18 | 2020-2024 | Rayaldee |
| Bard Peripheral Vascular, INC. | $135.37 | 2019 | |
| Vifor Pharma, INC. | $130.68 | 2021-2024 | Veltassa |
| Genzyme Corporation | $125.55 | 2021-2023 | |
| Fresenius USA Marketing, INC. | $121.14 | 2019-2023 | Velphoro |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $116.81 | 2024-2025 | Keveyis |
| Baxter Healthcare | $103.47 | 2021-2025 | Renal - Pd |
| Glaxosmithkline, LLC. | $95.92 | 2022-2023 | Benlysta, Jesduvroq |
| Calliditas Therapeutics US INC. | $82.34 | 2023-2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $73.79 | 2022-2023 | Gattex |
| Horizon Therapeutics Plc | $73.16 | 2023 | Krystexxa |
| Alexion Pharmaceuticals, INC. | $60.76 | 2021-2023 | Ultomiris |
| Aurinia Pharma U.S., INC. | $50.73 | 2022-2023 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $40.52 | 2021-2022 | |
| Cycle Pharmaceuticals INC | $35.79 | 2025 | Venxxiva |
| Pfizer INC. | $34.99 | 2023-2024 | |
| Ardelyx, INC. | $26.29 | 2024 | Ibsrela |
| Lilly USA, LLC | $25.43 | 2024 | Mounjaro |
| Nxstage Medical, INC. | $24.04 | 2022 | |
| Arbor Pharmaceuticals, INC. | $19.33 | 2020 | |
| Azurity Pharmaceuticals, INC. | $18.76 | 2023 | Horizant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishna Sury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.